Matthew S. Davids, MD
Adding ibrutinib (Imbruvica) to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia (CLL) induced negative minimum residual disease (MRD) status in bone marrow for 83% of patients, according to results from preliminary clinical study.1
Enrollment in the expansion study began in April, and 30 patients accrued since then. Davids said five patients opted to discontinue ibrutinib, and none has recurred.
- Davids MS, Kim HT, Brander DM, et al. A multicenter, phase ii study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients. Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 496.
- Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208-215.
- Brown JR, Barrients JC, Barr PM, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125:2915-2922.
... to read the full story